Mizuho Maintains Buy on Sarepta Therapeutics, Raises Price Target to $179
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Uy Ear maintains a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) and raises the price target from $145 to $179.
May 17, 2024 | 11:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Uy Ear maintains a Buy rating on Sarepta Therapeutics and raises the price target from $145 to $179.
The raised price target and maintained Buy rating from a reputable analyst at Mizuho is likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100